Management ChangeOct 28, 2026, 09:06 AM
Arcutis Biotherapeutics Appoints Dr. Robert Scott to Board of Directors
AI Summary
Arcutis Biotherapeutics, Inc. announced the appointment of Dr. Robert Scott to its Board of Directors and the Nominating and Corporate Governance Committee. Dr. Scott, a seasoned pharmaceutical industry executive with extensive experience in drug development and approvals, was appointed as a Class II director. His appointment is part of an increase in the Board's size from ten to eleven directors. Dr. Scott will receive compensation in line with the Company's non-employee director program, including an initial stock option award and prorated equity and cash retainers.
Key Highlights
- Arcutis Biotherapeutics appointed Dr. Robert Scott to its Board of Directors and Nominating and Corporate Governance Committee.
- Dr. Scott, 73, brings over 40 years of pharmaceutical industry leadership experience, including roles at AbbVie and Amgen.
- As a non-employee director, Dr. Scott will receive an initial stock option award for 20,507 shares.
- He is eligible for a prorated annual equity award valued at approximately $350,000 and a prorated annual cash retainer of $50,000.
- Dr. Scott will also receive a prorated $5,000 retainer for his service on the Nominating and Corporate Governance Committee.
Price Impact
More from ARQT